Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7486)
All Articles published online
|
Publishing Process of This Article
|
Nov 28, 2019 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i44/6551.htm |
| Number | Citing Articles |
| 1 |
Marta Giachello, Lucia Leporatti, Rosella Levaggi, Marcello Montefiori. The illness trap: The impact of disability benefits on willingness to receive HCV treatment. Economics & Human Biology 2024; 52: 101352 doi: 10.1016/j.ehb.2024.101352
|
| 2 |
Xizi Deng, Zhiwei Liang, Weiping Cai, Feng Li, Junbin Li, Fengyu Hu, Yun Lan. Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China. Virology Journal 2022; 19(1) doi: 10.1186/s12985-022-01849-4
|
| 3 |
Wencong Li, Jing Liang, Jihong An, Lingdi Liu, Yihui Hou, Lu Li, Wen Zhao, Luyao Cui, Ningning Xue, Zaid Al-Dhamin, Tao Han, Yuemin Nan, Liaoyun Zhang, Alessandro Granito. Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. Canadian Journal of Gastroenterology and Hepatology 2022; 2022: 1 doi: 10.1155/2022/7395506
|
| 4 |
Mi Seon Park, Young-Mo Yang, Ki Hyun Park, Hyonok Yoon, Ju Sin Kim, Eun Joo Choi. Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital. Korean Journal of Clinical Pharmacy 2022; 32(3): 191 doi: 10.24304/kjcp.2022.32.3.191
|
| 5 |
Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi. Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose. Pharmacology Research & Perspectives 2021; 9(4) doi: 10.1002/prp2.811
|
| 6 |
Hui Jun Zhou, Jing Cao, Hui Shi, Nasheen Naidoo, Sherehe Semba, Pei Wang, Yi Fan Fan, Shui Cheng Zhu. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Frontiers in Public Health 2021; 9 doi: 10.3389/fpubh.2021.779215
|
| 7 |
Tingting Mei, Xiaojie Huang, Shan Tang, Menglu Liu, Wenyan Zhang, Haibin Yu. Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis. Lipids in Health and Disease 2024; 23(1) doi: 10.1186/s12944-023-01957-2
|
| 8 |
Nahed Mohammed Hawsawi, Tamer Saber, Hussein M. Salama, Walaa S. Fouad, Howaida M. Hagag, Hayaa M. Alhuthali, Emad M. Eed, Taisir Saber, Khadiga A. Ismail, Hesham H. Al Qurashi, Samir Altowairqi, Mohmmad Samaha, Dalia El-Hossary. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital. Tropical Medicine and Infectious Disease 2023; 8(2): 92 doi: 10.3390/tropicalmed8020092
|
| 9 |
Resha Dermawansyah Rusman, Nu’man AS Daud, Muhammad Luthfi Parewangi, Syakib Bakri, Andi Makbul Aman, Haerani Rasyid, Arifin Seweng, Akiko Syawalidhany Tahir. Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00217-9
|
| 10 |
Huan-Keat Chan, Mohamed Azmi Hassali, Rosaida Md Said, Haniza Omar, Noor Aliza Abd Mutalib, Frederick Walter De Rozario, Muhammad Radzi Abu Hassan. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. Hepatitis Monthly 2021; 21(3) doi: 10.5812/hepatmon.113226
|
| 11 |
Innocent Kamali, Dale A. Barnhart, Françoise Nyirahabihirwe, Jean de la Paix Gakuru, Mariam Uwase, Esdras Nizeyumuremyi, Stephen Walker, Christian Mazimpaka, Jean de Dieu Gatete, Jean Damascene Makuza, Janvier Serumondo, Fredrick Kateera, Jean d’Amour Ndahimana. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach. BMC Infectious Diseases 2021; 21(1) doi: 10.1186/s12879-021-05920-3
|
| 12 |
Heba Shawky, Reem El-Shenawy, Naiera M. Helmy. Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients. Human Antibodies 2021; 29(4): 263 doi: 10.3233/HAB-211504
|